Xtandi 80 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DR26FQLL3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,021
Award facts
- Contract value 100% obligated
- $17,021.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $17,021.36 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 60 tablets of XTANDI 80 MG, an oncology treatment. The delivery order, issued on November 18, 2025, with an ultimate completion date of November 19, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award was issued under DMS Pharmaceutical Group's recently established Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense medical facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical supplier within the military healthcare pharmaceutical supply chain, with a robust portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The underlying IDC, designated as contract SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 with an ultimate completion date of December 31, 2036, positioning the company as one of multiple regional prime vendor contractors. The 30-month base period with three 30-month option periods enables the Defense Logistics Agency to issue firm fixed-price delivery orders for pharmaceutical products to support recurring medical supply needs across military healthcare facilities globally.
Quick answers
Who was awarded contract SPE2DR26FQLL3?
SPE2DR26FQLL3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 18, 2025.
How much is contract SPE2DR26FQLL3 worth?
The government has obligated $17,021 on SPE2DR26FQLL3.
Is contract SPE2DR26FQLL3 an order under another contract?
Yes. SPE2DR26FQLL3 is a delivery order under SPE2DR25D9354, an indefinite delivery contract.
Was contract SPE2DR26FQLL3 competed?
The extent of competition for SPE2DR26FQLL3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award